Preeclampsia (de novo proteinuric hypertension) is estimated to occur in approximately 3% of all pregnancies and is a leading cause of maternal and perinata lmortality and morbidity in the Westernworld79,80; together with other hypertensive disorders of pregnancy, preeclampsia is responsible for approximately 60,000 maternal deaths each year 81 and increases perinatal mortality 5 fold. 82Placental and maternal systemic oxidative stress are components of the syndrome 83 and contribute to a generalizedmaternal systemic inflammatory activation. 84 Placental ischemia reperfusioninjury has been implicated in excessiveproduction of ROS, causing release ofplacental factors that mediate the inflammatory responses